Gut bacteria's role in lymphoma treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at the bacteria living in your gut (your gut microbiome) to see if they affect how well lymphoma responds to treatment. It involves collecting stool and blood samples before and during your standard R-CHOP chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed large B-cell lymphoma (like diffuse large B-cell lymphoma) that hasn't been treated yet.
- Your doctor must plan to treat you with a standard chemotherapy called R-CHOP.
- You need a PET scan before starting treatment to see how far the lymphoma has spread.
- You must be 18 years or older.
- You cannot be pregnant, have a serious infection, an ileostomy, or certain other health problems like severe heart or organ issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for tumor “signatures” (including tiny RNA molecules, or miRNA) to predict outcomes in people with relapsed or resistant diffuse large B‑cell lymphoma (DLBCL). Your tissue samples help researchers see which patients may benefit from standard chemotherapy plus antibody treatment.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This Phase 2 trial tests a PD-1 antibody (anti–PD-1) added to standard R-CHOP chemotherapy for certain people with diffuse large B-cell lymphoma (DLBCL) who have a p53 mutation and tumor PD-L1 expression. It may help shrink lymphoma more effectively when these tumor markers are present.
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
This trial tests whether adding personalized, low-dose radiation therapy to standard chemotherapy improves outcomes for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The radiation plan is tailored based on how well your cancer responds to chemotherapy early on.
This study checks whether an electronic system that monitors symptoms helps care for people with newly diagnosed large B-cell lymphoma starting R-CHOP or a smaller R-mini-CHOP dose. It mainly looks at capturing events and symptom information rather than changing your cancer treatment.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.